Welcome to the Horizon 2020 atherosclerosis research program website
On January 30, 2017, the 2nd Governing Council meeting took place in Munich. This meeting was convened by the Work package 2 leader (Esther Lutgens, Ludwig-Maximilians-Universität München) and hosted at the Hilton Conference center nearby Munich Airport. The consortium members widely discussed the detailed project activities and workplan (Work-Packages and Tasks) and the main objectives of the
On January 30, 2017, the 2nd REPROGRAM Governing Council meeting is organized in Munich, Germany. All consortium partners are invited. Beside progress presentations of each work package leader, networking and training activities are scheduled.
ERA-NET on Cardiovascular Diseases Joint Transnational Call for Proposals 2017 (JTC 2017): “Mechanisms of early atherosclerosis and/or plaque instability in Coronary Artery Disease” CVD research is not only a crucial area in health research overall, but could become an outstanding example of research driven innovation across Europe. An effective coordination of research at national
Efforts to reverse the pathologic consequences of vulnerable plaques are often stymied by the complex treatment resistant pro-inflammatory environment within the plaque. This suggests that pro-atherogenic stimuli, such as LDL cholesterol and high fat diets may impart longer lived signals on (innate) immune cells that persist even after reversing the pro-atherogenic stimuli. Recently, a series
Background: Increasing numbers of patients (up to 40 %) with rheumatoid arthritis (RA) achieve remission, yet it remains to be elucidated whether this also normalizes their cardiovascular risk. Short-term treatment with TNF inhibitors lowers arterial wall inflammation, but not to levels of healthy controls. We investigated whether RA patients in long-term remission are characterized by
Every year The Radboud Center for Infectious Diseases organizes the international symposium ‘Summer Frontiers of Science’ on a cutting edge subject in infection and immunology. www.radboudumc.nl/summerfrontiers The subject of ‘Systems Biology of Innate Immunity’ will cover novel aspects on functional genomics, epigenomics, transcriptomics, microbiome and immunometabolism, related to the understanding of innate immune responses.
The European Atherosclerosis Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. Through a regular series of Featured Commentaries EAS puts into
AMC Researchers Siroon Bekkering and Simone Verweij both awarded Best Presentor at the Lipoprotein(a) Satellite Meeting (From Bench to Bedside) in Innsbruck (2016). The AMC department of Vascular Medicine (Erik Stroes) is imbedded in the department of Internal Medicine, and has a strong focus on translational research aimed at pathophysiology, diagnosis and treatment of atherosclerotic
BACKGROUND AND AIMS: We have recently reported that monocytes can undergo functional and transcriptional reprogramming towards a long-term pro-inflammatory phenotype after brief in vitro exposure to atherogenic stimuli such as oxidized LDL. This process is termed ‘trained immunity’, and is mediated by epigenetic remodeling and a metabolic switch towards increased aerobic glycolysis. We hypothesize that
BACKGROUND: Innate immune memory or ‘trained immunity’ has recently been described as an important property of cells of the innate immune system. Due to the increased interest in this important new field of immunological investigation we sought to determine the optimal conditions for an in-vitro experimental protocol of monocyte training using three of the most
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.